(Q37301968)

19 August 2017

1 reference

title

Extending half-life in coagulation factors: where do we stand? (English)

1 reference

19 August 2017

David Lillicrap

1

1 reference

19 August 2017

publication date

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

122 Suppl 4

1 reference

19 August 2017

page(s)

S2-8

1 reference

Blood coagulation factor VIII: An overview

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Clearance mechanisms of von Willebrand factor and factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Clearance of von Willebrand factor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-related Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Structure of human factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Peptide and protein PEGylation: a review of problems and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Synthesis and characterization of poly(ethylene glycol)-insulin conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

The tertiary structure and domain organization of coagulation factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Pharmaceutical strategies utilizing recombinant human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Development of a long-acting insulin analog using albumin fusion technology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

Prolonged in-vivo half-life of factor VIIa by fusion to albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2808%2970027-6

7 January 2021

10.1016/S0049-3848(08)70027-6

Identifiers

DOI

1 reference

19 August 2017

1 reference